27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Twenty formal carers employed in three nursing homes narrated 92 episodes of lucidity (ELs) in people with severe dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Ever since Kiloh (1961)[2] coined the term pseudo-dementia, it has been used a little loosely for describing the cognitive deficits in depression, especially, which is found in old age. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Twenty-two subjects with presumed senile dementia of the Alzheimer's type (SDAT), twenty-two with dementia other than SDAT, twenty with aphasia, and seventeen healthy controls over 50 years of age were examined for intrusions and perseverations. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We used 1387 safety event reports for model development, 989 (71.3%) reports related to situational factors and 119 (8.6%) reports related to active failures. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The CatBoost-based risk model achieved an area under the receiver-operating characteristic curve (AUROC) of 0.814 (<70 years) and 0.892 (<65 years). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Three themes identified include (a) LOVOT's role in supporting engagement and stimulating conversation, (b) the irreplaceability of human touch and emotional nuances, and (c) concerns about ownership and equitable resource allocation. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Random Forest achieves the highest accuracy of 97% on clinical data, while CNN achieves the best overall performance of 94% in MRI-based staging. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Utilizing clinical data, the highest ROC AUC scores attained were 0.989, 0.927, and 0.907 for the identification of the CN, MCI, and dementia stages, respectively. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Accurate and reproducible electroencephalography (EEG)-based classification of dementia remains a key challenge in computational neurodiagnostics. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia poses an on-going Canadian challenge due to an aging population, with cases projected to rise significantly by 2050. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Physical inactivity and low fitness have become global health concerns. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Lewy body dementias (LBD), comprising dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), are defined by misfolded α-synuclein aggregation. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In this paper, we develop a method based on support vector machines (SVMs) that starting from the protein sequence information can predict whether a new phenotype derived from a nsSNP can be related to a genetic disease in humans. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Many secretory proteins and peptides are synthesized as inactive precursors that in addition to signal peptide cleavage undergo post-translational processing to become biologically active polypeptides. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Mild cognitive impairment (MCI) is a transitional stage between age-related cognitive decline and Alzheimer's disease (AD). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The brain is considered to be an immune privileged site, because the blood-brain barrier limits entry of blood borne cells and proteins into the central nervous system (CNS). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Age-related cognitive changes often include difficulties in retrieving memories, particularly those that rely on personal experiences within their temporal and spatial contexts (i.e., episodic memories). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
There has been a growing need for in vitro models of neurodegenerative diseases such as Alzheimer's disease that would enable a better understanding of etiology and faster development of treatment strategies. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Conceptual knowledge provides the basis on which we bring meaning to our world. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The accurate diagnosis of Alzheimer's disease (AD) is essential for patient care and will be increasingly important as disease modifying agents become available, early in the course of the disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Neurodegenerative disorders, such as Alzheimer's disease, are associated with changes in multiple neuroimaging and biological measures. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Normal aging and mild Alzheimer's disease (AD) are associated with declines in navigational skills, including allocentric and egocentric representations, cognitive mapping, landmark processing, and spatial memory. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recently, there have been great interests for computer-aided diagnosis of Alzheimer's disease (AD) and its prodromal stage, mild cognitive impairment (MCI). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent neuroimaging studies have demonstrated that both remembering the past and simulating the future activate a core neural network including the medial temporal lobes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The molecular neuroscience revolution has begun to rekindle interest in fundamental neuroanatomy. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →